On October 25, 2019, Iconovo announced a strategic initiative to develop ICOpre™ as an alternative generic inhaler platform to the Ellipta® inhaler from GSK. ICOpre™ will be developed for a global registration including the USA as an AB-rated substitution for Ellipta® .
Iconovo possess a unique combination of engineering and pharmaceutical expertise, where Iconovo can provide the optimal combination of uniquely designed inhalers and tailored formulations that deliver the right dose to the lungs.
Iconovo offers reliable, competitively priced dry powder inhaler solutions based on four differentiated technical platforms. It means that pharmaceutical companies seeking a fast and safe way to reach the market with their products can feel assured that Iconovo will reduce project risk, development cost and shorten time to commercialization.
Iconovo offers three inhaler platforms immediately available for customization with inhalation powder, and soon also ICOpre™ as a fourth inhaler platform. A comprehensive service package is offered by Iconovo including device design, formulation development, analytical testing and documentation.
The highly skilled employees of Iconovo have significant experience in developing both inhaler devices and dry powder formulation in our own laboratory for formulation development, inhaler customization and characterization of inhaler product. In addition, there is an extensive network of inhalation expertise that can support with additional analysis when relevant.
Ellipta is an inhaler developed by GSK that is used as the inhaler of choice for the new products launched to treat asthma and COPD. Ellipta is currently approved with five different products, Breo® (vilanterol-fluticasone furoate), Anoro® (vilanterol), Incruse® (umeclidinium), Trelegy® (vilanterol-fluticasone furoate-umeclidinium) and Arnuity® (fluticasone furoate). These products combined represent the largest future market opportunity for generic launches of inhalers as other best-selling inhaled respiratory products have already lost its market exclusivity.
The combined sales for the Ellipta® products mentioned above and forecasted for 2023 is the following: